These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 18308358)

  • 1. APOBEC3G restricts early HIV-1 replication in the cytoplasm of target cells.
    Anderson JL; Hope TJ
    Virology; 2008 May; 375(1):1-12. PubMed ID: 18308358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. APOBEC3G inhibits elongation of HIV-1 reverse transcripts.
    Bishop KN; Verma M; Kim EY; Wolinsky SM; Malim MH
    PLoS Pathog; 2008 Dec; 4(12):e1000231. PubMed ID: 19057663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytoplasmic APOBEC3G restricts incoming Vif-positive human immunodeficiency virus type 1 and increases two-long terminal repeat circle formation in activated T-helper-subtype cells.
    Vetter ML; D'Aquila RT
    J Virol; 2009 Sep; 83(17):8646-54. PubMed ID: 19535442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. APOBEC3G complexes decrease human immunodeficiency virus type 1 production.
    Martin KL; Johnson M; D'Aquila RT
    J Virol; 2011 Sep; 85(18):9314-26. PubMed ID: 21752914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. APOBEC3G inhibits HIV-1 RNA elongation by inactivating the viral trans-activation response element.
    Nowarski R; Prabhu P; Kenig E; Smith Y; Britan-Rosich E; Kotler M
    J Mol Biol; 2014 Jul; 426(15):2840-53. PubMed ID: 24859335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exosomes packaging APOBEC3G confer human immunodeficiency virus resistance to recipient cells.
    Khatua AK; Taylor HE; Hildreth JE; Popik W
    J Virol; 2009 Jan; 83(2):512-21. PubMed ID: 18987139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. APOBEC3G and APOBEC3F Act in Concert To Extinguish HIV-1 Replication.
    Krisko JF; Begum N; Baker CE; Foster JL; Garcia JV
    J Virol; 2016 May; 90(9):4681-4695. PubMed ID: 26912618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Various strategies for developing APOBEC3G protectors to circumvent human immunodeficiency virus type 1.
    Bao Q; Zhou J
    Eur J Med Chem; 2023 Mar; 250():115188. PubMed ID: 36773550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. APOBEC3G and APOBEC3F require an endogenous cofactor to block HIV-1 replication.
    Han Y; Wang X; Dang Y; Zheng YH
    PLoS Pathog; 2008 Jul; 4(7):e1000095. PubMed ID: 18604271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Redoxal, an inhibitor of de novo pyrimidine biosynthesis, augments APOBEC3G antiviral activity against human immunodeficiency virus type 1.
    Pery E; Sheehy A; Miranda Nebane N; Misra V; Mankowski MK; Rasmussen L; Lucile White E; Ptak RG; Gabuzda D
    Virology; 2015 Oct; 484():276-287. PubMed ID: 26141568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a novel HIV-1 inhibitor targeting Vif-dependent degradation of human APOBEC3G protein.
    Pery E; Sheehy A; Nebane NM; Brazier AJ; Misra V; Rajendran KS; Buhrlage SJ; Mankowski MK; Rasmussen L; White EL; Ptak RG; Gabuzda D
    J Biol Chem; 2015 Apr; 290(16):10504-17. PubMed ID: 25724652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-1 subtype variability in Vif derived from molecular clones affects APOBEC3G-mediated host restriction.
    Lisovsky I; Schader SM; Sloan RD; Oliveira M; Coutsinos D; Bernard NF; Wainberg MA
    Intervirology; 2013; 56(4):258-64. PubMed ID: 23689841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism of Enhanced HIV Restriction by Virion Coencapsidated Cytidine Deaminases APOBEC3F and APOBEC3G.
    Ara A; Love RP; Follack TB; Ahmed KA; Adolph MB; Chelico L
    J Virol; 2017 Feb; 91(3):. PubMed ID: 27881650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human immunodeficiency virus type 1 replication and regulation of APOBEC3G by peptidyl prolyl isomerase Pin1.
    Watashi K; Khan M; Yedavalli VR; Yeung ML; Strebel K; Jeang KT
    J Virol; 2008 Oct; 82(20):9928-36. PubMed ID: 18684817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dimerization regulates both deaminase-dependent and deaminase-independent HIV-1 restriction by APOBEC3G.
    Morse M; Huo R; Feng Y; Rouzina I; Chelico L; Williams MC
    Nat Commun; 2017 Sep; 8(1):597. PubMed ID: 28928403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The HDAC6/APOBEC3G complex regulates HIV-1 infectiveness by inducing Vif autophagic degradation.
    Valera MS; de Armas-Rillo L; Barroso-González J; Ziglio S; Batisse J; Dubois N; Marrero-Hernández S; Borel S; García-Expósito L; Biard-Piechaczyk M; Paillart JC; Valenzuela-Fernández A
    Retrovirology; 2015 Jun; 12():53. PubMed ID: 26105074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cellular antiviral protein APOBEC3G interacts with HIV-1 reverse transcriptase and inhibits its function during viral replication.
    Wang X; Ao Z; Chen L; Kobinger G; Peng J; Yao X
    J Virol; 2012 Apr; 86(7):3777-86. PubMed ID: 22301159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. APOBEC3F and APOBEC3G inhibit HIV-1 DNA integration by different mechanisms.
    Mbisa JL; Bu W; Pathak VK
    J Virol; 2010 May; 84(10):5250-9. PubMed ID: 20219927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deaminase-independent inhibition of HIV-1 reverse transcription by APOBEC3G.
    Iwatani Y; Chan DS; Wang F; Stewart-Maynard K; Sugiura W; Gronenborn AM; Rouzina I; Williams MC; Musier-Forsyth K; Levin JG
    Nucleic Acids Res; 2007; 35(21):7096-108. PubMed ID: 17942420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of heat-shock protein 70 by prostaglandin A₁ inhibits HIV-1 Vif-mediated degradation of APOBEC3G.
    Sugiyama R; Abe M; Nishitsuji H; Murakami Y; Takeuchi H; Takaku H
    Antiviral Res; 2013 Sep; 99(3):307-11. PubMed ID: 23831493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.